John Griffin - Kuros Biosciences VP Sales
| CSBTF Stock | USD 27.34 0.26 0.94% |
Insider
John Griffin is VP Sales of Kuros Biosciences AG
| Phone | 41 44 733 4747 |
| Web | https://www.kuros.ch |
John Griffin Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Griffin against Kuros Biosciences pink sheet is an integral part of due diligence when investing in Kuros Biosciences. John Griffin insider activity provides valuable insight into whether Kuros Biosciences is net buyers or sellers over its current business cycle. Note, Kuros Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kuros Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Griffin over three months ago Acquisition by John Griffin of 200 shares of Harte Hanks at 5.6 subject to Rule 16b-3 | ||
John Griffin over six months ago Acquisition by John Griffin of 200 shares of Harte Hanks at 5.62 subject to Rule 16b-3 | ||
John Griffin over six months ago Acquisition by John Griffin of 200 shares of Harte Hanks at 5.66 subject to Rule 16b-3 | ||
John Griffin over six months ago Acquisition by John Griffin of 100 shares of Harte Hanks at 5.649 subject to Rule 16b-3 |
Kuros Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.0667) % which means that it has lost $0.0667 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1409) %, meaning that it generated substantial loss on money invested by shareholders. Kuros Biosciences' management efficiency ratios could be used to measure how well Kuros Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Pederson | Abbott Laboratories | 59 | |
| Mary Moreland | Abbott Laboratories | 59 | |
| Preston Wells | Stryker | N/A | |
| Alejandro Wellisch | Abbott Laboratories | 49 | |
| Charles Brynelsen | Abbott Laboratories | 63 | |
| Alan Douville | Stryker | N/A | |
| Andrea Wainer | Abbott Laboratories | 55 | |
| Robert Cohen | Stryker | N/A | |
| Elaine Leavenworth | Abbott Laboratories | 65 | |
| Christopher Scoggins | Abbott Laboratories | 54 | |
| Vance Brown | Boston Scientific Corp | 55 | |
| James Young | Abbott Laboratories | N/A | |
| Jereme Sylvain | DexCom Inc | 44 | |
| Paul Flynn | DexCom Inc | 55 | |
| Lisa Tatum | Stryker | 53 | |
| Spencer Stiles | Stryker | 48 | |
| John Ginascol | Abbott Laboratories | 62 | |
| Randel Woodgrift | Abbott Laboratories | 59 | |
| Heisz Stone | Edwards Lifesciences Corp | 58 | |
| Lisa Earnhardt | Abbott Laboratories | 55 | |
| Sammy Karam | Abbott Laboratories | 59 | |
Management Performance
| Return On Equity | -0.14 | |||
| Return On Asset | -0.0667 |
Kuros Biosciences Leadership Team
Elected by the shareholders, the Kuros Biosciences' board of directors comprises two types of representatives: Kuros Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kuros. The board's role is to monitor Kuros Biosciences' management team and ensure that shareholders' interests are well served. Kuros Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kuros Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BSc BS, CEO Director | ||
| Florence Groot, Head Devel | ||
| Philippe Saudan, Chief Scientific Officer and VP | ||
| Oliver Kronenberg, Legal Counsel | ||
| MS DO, VP Affairs | ||
| Christopher Fair, Chief Officer | ||
| MBA MBA, Chief Officer | ||
| Alistair Irvine, Member of the Management Board, Chief Business Officer | ||
| Charlie Campion, VP Sales | ||
| John Griffin, VP Sales |
Kuros Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Kuros Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | |||
| Return On Asset | -0.0667 | |||
| Profit Margin | (0.74) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 40.53 M | |||
| Shares Outstanding | 36.54 M | |||
| Shares Owned By Insiders | 35.33 % | |||
| Shares Owned By Institutions | 16.83 % | |||
| Price To Earning | 0.33 X | |||
| Price To Book | 0.79 X |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Kuros Pink Sheet
Kuros Biosciences financial ratios help investors to determine whether Kuros Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kuros with respect to the benefits of owning Kuros Biosciences security.